J2329 HCPCS Level II code: Injection, ublituximab-xiiy, 1mg
J2329 is the HCPCS code for “Injection, ublituximab-xiiy, 1mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J2329Injection, ublituximab-xiiy, 1mg
Short description: Inj ublituximab-xiiy, 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J2329 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jul 1, 2023
Where J2329 sits
- 1J codesDrugs administered other than orally
- 2Active code J2329Injection, ublituximab-xiiy, 1mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J2329 mean?
J2329 is the HCPCS code for “Injection, ublituximab-xiiy, 1mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J2329?
CMS lists J2329’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J2329
All J codesJ2315Injection, naltrexone, depot form, 1 mgJ2320Injection, nandrolone decanoate, up to 50 mgJ2323Injection, natalizumab, 1 mgJ2325Injection, nesiritide, 0.1 mgJ2326Injection, nusinersen, 0.1 mgJ2327Injection, risankizumab-rzaa, intravenous, 1 mgJ2350Injection, ocrelizumab, 1 mgJ2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsqJ2353Injection, octreotide, depot form for intramuscular injection, 1 mgJ2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgJ2355Injection, oprelvekin, 5 mgJ2356Injection, tezepelumab-ekko, 1 mg